← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Leukogene Therapeutics, Inc.
Charleston, SC
$5,749,988
Total funding
6
Grants
Funding over time
peak $1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,749,988 · 6
By mechanism
R42$2,671,746 · 2
R44$2,268,465 · 1
R41$809,777 · 3
Investigators at Leukogene Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma$1,015,871
R42 · FY2019 · CA
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma$984,129
R42 · FY2018 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$782,691
R44 · FY2023 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$742,887
R44 · FY2024 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$742,887
R44 · FY2025 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma$671,746
R42 · FY2022 · CA
Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinoma$362,118
R41 · FY2021 · CA
Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma$224,701
R41 · FY2013 · CA
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma$222,958
R41 · FY2016 · CA